Mind Medicine Mindmed Inc (MNMD)

$14.20 +0.81 (6.05%)
Market Cap 1.08B
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.22
Volume 5,325,600
Avg Vol 1,811,420
Day's Range N/A - N/A
Shares Out 76.09M
Stochastic %K 91%
Beta 2.55
Analysts Strong Sell
Price Target $24.91

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
RunnerSignals
RunnerSignals Nov. 1 at 8:54 PM
Momentum Plays Flying Under the Radar $ASX $MNMD $TSEM just posted 5–7-day win streaks while $BRZE $MGTX quietly build. Low volume + strong technicals = opportunities hiding in plain sight https://stocksrunner.com/news/2025-11-01-low-volume-stocks-with-momentum-worth-watching
0 · Reply
trading_signal
trading_signal Nov. 1 at 9:36 AM
$MNMD 16 TP next 🍄
0 · Reply
trading_signal
trading_signal Nov. 1 at 9:36 AM
$MNMD what a beautiful day today finally pushing 14+ 🙏
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Nov. 1 at 8:56 AM
$MNMD's Institutional Investor ownership
0 · Reply
Rocketzz
Rocketzz Nov. 1 at 4:19 AM
$MNMD
3 · Reply
Rocketzz
Rocketzz Nov. 1 at 4:12 AM
$MNMD Trick or Treat Goral!
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Oct. 31 at 11:31 PM
$MNMD 50
0 · Reply
Kaloo_03
Kaloo_03 Oct. 31 at 11:15 PM
$MNMD This chart is JUICY!!!
0 · Reply
Cat651
Cat651 Oct. 31 at 9:31 PM
$MNMD 15’7 next week for sure,,,but it would want to cross that,,19’8 next. just saying outloud
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Oct. 31 at 9:14 PM
$MNMD Cup and Handle forming on the monthly
1 · Reply
Latest News on MNMD
MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 2 days ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 3 days ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 3 days ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Announces New Employee Inducement Grant

Oct 14, 2025, 4:01 PM EDT - 18 days ago

MindMed Announces New Employee Inducement Grant

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 18 days ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 19 days ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

MindMed Announces New Employee Inducement Grants

Sep 22, 2025, 4:01 PM EDT - 5 weeks ago

MindMed Announces New Employee Inducement Grants

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 6 weeks ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 2 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 2 months ago

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 3 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 3 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 5 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 5 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 6 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 6 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 6 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 6 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 7 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 8 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 8 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 8 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 9 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 9 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 9 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 11 months ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 11 months ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 11 months ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 11 months ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 11 months ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

MindMed to Participate in Upcoming Investor Conferences

Nov 13, 2024, 7:00 AM EST - 1 year ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Pacific Defense Announces US Army CMFF Program Team

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Aug 9, 2024, 8:44 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

Aug 7, 2024, 2:29 PM EDT - 1 year ago

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 6, 2024, 4:01 PM EDT - 1 year ago

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

RunnerSignals
RunnerSignals Nov. 1 at 8:54 PM
Momentum Plays Flying Under the Radar $ASX $MNMD $TSEM just posted 5–7-day win streaks while $BRZE $MGTX quietly build. Low volume + strong technicals = opportunities hiding in plain sight https://stocksrunner.com/news/2025-11-01-low-volume-stocks-with-momentum-worth-watching
0 · Reply
trading_signal
trading_signal Nov. 1 at 9:36 AM
$MNMD 16 TP next 🍄
0 · Reply
trading_signal
trading_signal Nov. 1 at 9:36 AM
$MNMD what a beautiful day today finally pushing 14+ 🙏
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Nov. 1 at 8:56 AM
$MNMD's Institutional Investor ownership
0 · Reply
Rocketzz
Rocketzz Nov. 1 at 4:19 AM
$MNMD
3 · Reply
Rocketzz
Rocketzz Nov. 1 at 4:12 AM
$MNMD Trick or Treat Goral!
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Oct. 31 at 11:31 PM
$MNMD 50
0 · Reply
Kaloo_03
Kaloo_03 Oct. 31 at 11:15 PM
$MNMD This chart is JUICY!!!
0 · Reply
Cat651
Cat651 Oct. 31 at 9:31 PM
$MNMD 15’7 next week for sure,,,but it would want to cross that,,19’8 next. just saying outloud
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Oct. 31 at 9:14 PM
$MNMD Cup and Handle forming on the monthly
1 · Reply
Beachlife22
Beachlife22 Oct. 31 at 9:11 PM
$MNMD here’s to the MNMD family, been great couple of weeks/ months only to get better💰💰💰😎
1 · Reply
PsychedStocks
PsychedStocks Oct. 31 at 8:37 PM
$CYBN Cybin Announces Closing of $175 Million Registered Direct Offering $CMPS $MNMD $ATAI $SPY https://ir.cybin.com/investors/news/news-details/2025/Cybin-Announces-Closing-of-175-Million-Registered-Direct-Offering/default.aspx
0 · Reply
Rocketzz
Rocketzz Oct. 31 at 7:21 PM
$MNMD
0 · Reply
DeadshotResearch
DeadshotResearch Oct. 31 at 5:36 PM
$MNMD yipee!
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Oct. 31 at 4:17 PM
$MNMD 50
2 · Reply
fmalad
fmalad Oct. 31 at 4:16 PM
$MNMD look for a buyout at 25-35 per share. Most likely candidate would be Pfizer!
2 · Reply
Rocketzz
Rocketzz Oct. 31 at 4:02 PM
$MNMD what a chart, damn. Even green on the 5yr
0 · Reply
QuarterTonLazer
QuarterTonLazer Oct. 31 at 4:01 PM
$MNMD great day! I am with @MichaelNaussCMT let's melt on up to $50. This stock hasn't even begun to catch fire.
0 · Reply
Vineezee
Vineezee Oct. 31 at 3:22 PM
$MNMD gentlemen, I bought at the top and endured the reverse split. DCAd down when it look like all was lost but never lost conviction bc the science behind the thesis will be proven. Today I am officially in the green after years of pain. LFG. Not selling 1 share until this a 10 bagger
2 · Reply
Horseman23
Horseman23 Oct. 31 at 2:14 PM
$MNMD
0 · Reply
BobbyCucumber
BobbyCucumber Oct. 31 at 2:13 PM
$MNMD Giddiup!!!
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Oct. 31 at 2:00 PM
$MNMD $50
0 · Reply